product name Methazolamide
Description: Methazolamide (also known as CL 8490) is a highly potent and selective inhibitor of carbonic anhydrase with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively. Methazolamide is used as a diuretic for the treatment of glaucoma. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors.
References: Bioorg Med Chem Lett. 2003;13(5):841-5; Am J Physiol Regul Integr Comp Physiol. 2009;297(3):R648-54.
236.27
Formula
C5H8N4O3S2
CAS No.
554-57-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 47 mg/mL (198.9 mM)
Water: < 1 mg/mL
Ethanol: 3 mg/mL (12.7 mM)
Solubility (In vivo)
Synonyms
CL 8490
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19404645
| In Vitro |
In vitro activity: Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively. Methazolamide is of strength equal to acetazolamide, another carbonic anhydrase inhibitor used to treat irregular breathing disorders. However, methazolamide differs from acetazolamide in that it fails to activate Ca2+-dependent potassium channels in skeletal muscles. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Methazolamide does not impair respiratory work performance in anesthetized rabbits. |
| Animal model | |
| Formulation & Dosage | |
| References | Bioorg Med Chem Lett. 2003 Mar 10;13(5):841-5; Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R648-54. |
Related Posts
product name Methazolamide
Description: Methazolamide (also known as CL 8490) is a highly potent and selective inhibitor of carbonic anhydrase with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively. Methazolamide is used as a diuretic for the treatment of glaucoma. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors.
References: Bioorg Med Chem Lett. 2003;13(5):841-5; Am J Physiol Regul Integr Comp Physiol. 2009;297(3):R648-54.
236.27
Formula
C5H8N4O3S2
CAS No.
554-57-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 47 mg/mL (198.9 mM)
Water: < 1 mg/mL
Ethanol: 3 mg/mL (12.7 mM)
Solubility (In vivo)
Synonyms
CL 8490
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19404645
| In Vitro |
In vitro activity: Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively. Methazolamide is of strength equal to acetazolamide, another carbonic anhydrase inhibitor used to treat irregular breathing disorders. However, methazolamide differs from acetazolamide in that it fails to activate Ca2+-dependent potassium channels in skeletal muscles. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Methazolamide does not impair respiratory work performance in anesthetized rabbits. |
| Animal model | |
| Formulation & Dosage | |
| References | Bioorg Med Chem Lett. 2003 Mar 10;13(5):841-5; Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R648-54. |